| Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer KD Miller, LI Chap, FA Holmes, MA Cobleigh, PK Marcom, ... Journal of clinical oncology 23 (4), 792-799, 2005 | 1682 | 2005 |
| Whole-genome analysis informs breast cancer response to aromatase inhibition MJ Ellis, L Ding, D Shen, J Luo, VJ Suman, JW Wallis, BA Van Tine, ... Nature 486 (7403), 353-360, 2012 | 1137 | 2012 |
| Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression CK Anders, DS Hsu, G Broadwater, CR Acharya, JA Foekens, Y Zhang, ... Journal of clinical oncology 26 (20), 3324-3330, 2008 | 1010 | 2008 |
| Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in … H Burris, H Hurwitz, EC Dees, A Dowlati, K Blackwell, B O'Neil, P Marcom, ... Journal of clinical oncology 23 (23), 5305-5313, 2005 | 790 | 2005 |
| Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer SM Tolaney, WT Barry, CT Dang, DA Yardley, B Moy, PK Marcom, ... New England Journal of Medicine 372 (2), 134-141, 2015 | 763 | 2015 |
| Circulating tumor cells from patients with advanced prostate and breast cancer display both epithelial and mesenchymal markersepithelial/mesenchymal markers on circulating … AJ Armstrong, MS Marengo, S Oltean, G Kemeny, RL Bitting, JD Turnbull, ... Molecular cancer research 9 (8), 997-1007, 2011 | 721 | 2011 |
| Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to … AD Seidman, D Berry, C Cirrincione, L Harris, H Muss, PK Marcom, ... Journal of Clinical Oncology 26 (10), 1642-1649, 2008 | 685 | 2008 |
| Changes in weight, body composition, and factors influencing energy balance among premenopausal breast cancer patients receiving adjuvant chemotherapy W Demark-Wahnefried, BL Peterson, EP Winer, L Marks, N Aziz, ... Journal of clinical oncology 19 (9), 2381-2389, 2001 | 626 | 2001 |
| Breast cancer, version 3.2020, NCCN clinical practice guidelines in oncology WJ Gradishar, BO Anderson, J Abraham, R Aft, D Agnese, KH Allison, ... Journal of the National Comprehensive Cancer Network 18 (4), 452-478, 2020 | 597 | 2020 |
| Randomized Phase II Neoadjuvant Comparison Between Letrozole, Anastrozole and Exemestane for Postmenopausal Women With Estrogen Receptor-Rich Stage 2 to 3 Breast Cancer … MJ Ellis, VJ Suman, J Hoog, L Lin, J Snider, A Prat Aparicio, JS Parker, ... Journal of Clinical Oncology, 2011, vol. 29, num. 17, p. 2342-2349, 2011 | 596 | 2011 |
| TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer LA Carey, HS Rugo, PK Marcom, EL Mayer, FJ Esteva, CX Ma, MC Liu, ... Journal of clinical oncology 30 (21), 2615, 2012 | 566 | 2012 |
| Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies NL Spector, W Xia, H Burris III, H Hurwitz, EC Dees, A Dowlati, B O'Neil, ... Journal of clinical oncology 23 (11), 2502-2512, 2005 | 470 | 2005 |
| Cancer Yield of Mammography, MR, and US in High-Risk Women: Prospective Multi-Institution Breast Cancer Screening Study1 CD Lehman, C Isaacs, MD Schnall, ED Pisano, SM Ascher, PT Weatherall, ... Radiology 244 (2), 381-388, 2007 | 457 | 2007 |
| Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor … HJ Burstein, LN Harris, PK Marcom, R Lambert-Falls, K Havlin, ... Journal of clinical oncology 21 (15), 2889-2895, 2003 | 431 | 2003 |
| NCCN guidelines insights: breast cancer, version 1.2017 WJ Gradishar, BO Anderson, R Balassanian, SL Blair, HJ Burstein, A Cyr, ... Journal of the National Comprehensive Cancer Network 15 (4), 433-451, 2017 | 417 | 2017 |
| Genetic/familial high-risk assessment: breast and ovarian MB Daly, JE Axilbund, S Buys, B Crawford, CD Farrell, S Friedman, ... Journal of the National Comprehensive Cancer Network 8 (5), 562-594, 2010 | 414* | 2010 |
| Breast cancer, version 4.2017, NCCN clinical practice guidelines in oncology WJ Gradishar, BO Anderson, R Balassanian, SL Blair, HJ Burstein, A Cyr, ... Journal of the National Comprehensive Cancer Network 16 (3), 310-320, 2018 | 372* | 2018 |
| Invasive breast cancer version 1.2016, NCCN clinical practice guidelines in oncology WJ Gradishar, BO Anderson, R Balassanian, SL Blair, HJ Burstein, A Cyr, ... Journal of the National Comprehensive Cancer Network 14 (3), 324-354, 2016 | 354 | 2016 |
| Breast cancer version 2.2015 WJ Gradishar, BO Anderson, R Balassanian, SL Blair, HJ Burstein, A Cyr, ... Journal of the National Comprehensive Cancer Network 13 (4), 448-475, 2015 | 341* | 2015 |
| Genetic/familial high-risk assessment: breast and ovarian, version 2.2015 MB Daly, R Pilarski, JE Axilbund, M Berry, SS Buys, B Crawford, M Farmer, ... Journal of the National Comprehensive Cancer Network 14 (2), 153-162, 2016 | 312 | 2016 |
